Dr Timothy A Blaney, PSYD | |
182 N Main St, Buffalo, WY 82834-1727 | |
(307) 684-9360 | |
(307) 684-5187 |
Full Name | Dr Timothy A Blaney |
---|---|
Gender | Male |
Speciality | Clinical Psychologist |
Experience | 27 Years |
Location | 182 N Main St, Buffalo, Wyoming |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1407955503 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
103TC0700X | Psychologist - Clinical | 328 (Wyoming) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr Timothy A Blaney, PSYD 489 N Desmet Ave, Buffalo, WY 82834-1641 Ph: (307) 684-9360 | Dr Timothy A Blaney, PSYD 182 N Main St, Buffalo, WY 82834-1727 Ph: (307) 684-9360 |
News Archive
Cardio Vascular Medical Device Corp., a leading developer of advanced cardiovascular surgery technology, today announced that the company's Board of Directors has decided to initiate patent applications in Europe, Canada and the Far East for its proprietary next-generation "steerable guidewire" applicable for all angioplasty (PCTA) procedures.
The National Math and Science Initiative and the Howard Hughes Medical Institute have awarded Louisiana Tech University a $1.45 million grant to support teacher preparation in science, technology, engineering and math (STEM) fields, as part of the national UTeach program.
The Ochnser Clinic Foundation recently announced that the 29th annual recipient of the prestigious Alton Ochnser Award is Charles H. Hennekens, M.D., Dr.P.H., the first Sir Richard Doll professor and senior academic advisor to the dean in the Charles E. Schmidt College of Medicine at Florida Atlantic University.
Pfizer said today it will work with the U.S. Food and Drug Administration (FDA) to add expanded risk information in the Celebrex label following an FDA decision announced this morning to require boxed warnings of potential cardiovascular risk for all COX-2 pain relievers and all NSAIDs, including older non-specific drugs such as ibuprofen and naproxen.
Epizyme, Inc., a clinical-stage company developing novel epigenetic therapies, today announced the U.S. Food and Drug Administration has lifted the partial clinical hold that had paused U.S.-based enrollment of new patients in its tazemetostat clinical trials.
› Verified 1 days ago
Thomas M Schnatterbeck, PSYD Psychologist Medicare: Not Enrolled in Medicare Practice Location: 182 N Main St, Buffalo, WY 82834 Phone: 307-763-0123 Fax: 307-684-9360 | |
Dr. Theresa Anne Faulkner, PH.D. Psychologist Medicare: Not Enrolled in Medicare Practice Location: 135 Pine St, Suite B, Buffalo, WY 82834 Phone: 307-684-5828 Fax: 307-684-5803 | |
Dr. Kim Knox Faulkner, PH.D. Psychologist Medicare: Not Enrolled in Medicare Practice Location: 135 Pine Street, Suite B, Buffalo, WY 82834 Phone: 307-684-5828 Fax: 307-684-5803 |